Aldeyra bags PhI­II-ready eye drug in He­lio buy­out; Liq­uid biop­sy mak­er On­co­Cyte shares sky­rock­et on val­i­da­tion da­ta

→ Eye drug de­vel­op­er Aldeyra Ther­a­peu­tics $ALDX, which counts J&J $JNJ as a part­ner, has bought pri­vate biotech He­lio Vi­sion for $10 mil­lion up­front in com­mon stock. The prize here is a Phase III-ready prod­uct can­di­date de­vel­oped by Har­vard pro­fes­sor Dean Eliott and Tomasz Stry­jew­s­ki, his col­league at the Mass­a­chu­setts Eye and Ear In­fir­mary. Now dubbed ADX-2191, the in­trav­it­re­al methotrex­ate treats pro­lif­er­a­tive vit­re­o­retinopa­thy, a se­ri­ous sight-threat­en­ing in­flam­ma­tion that typ­i­cal­ly hap­pens af­ter reti­nal surgery. He­lio is el­i­gi­ble for up to $15 mil­lion more in stock pay­ment as com­pa­ny co-founders con­tin­ue to con­sult with Aldeyra on clin­i­cal and reg­u­la­to­ry work.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER